CORCEPT THERAPEUTCS (HTD BE) stock market data APIs
€57.747
0(0%)
as of September 16, 2025
Try our APIs with
free plan!
CORCEPT THERAPEUTCS Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for HTD.BE.
Prev. Close
57.747
Open
57.747
High
57.747
Low
57.747
52 wk Range
35.4-105.2
Market Cap
1 917 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CORCEPT THERAPEUTCS data using free add-ons & libraries
Get CORCEPT THERAPEUTCS Fundamental Data
CORCEPT THERAPEUTCS Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CORCEPT THERAPEUTCS News
New
Alger Russell Innovation Index Updates for Third Quarter 2025
NEW YORK, Sept. 15, 2025 /PRNewswire/ -- Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovat...
Corcept’s (CORT) Multibagger Momentum Builds on Relacorilant and Expanding Commercial Footprint
Corcept Therapeutics Inc. (NASDAQ:CORT) is one of the best multibagger stocks to invest in right now. The company has recently revised its 2025 revenue guidance to $850-$900 million, down from the pre...
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
FDA assigns a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026 REDWOOD CITY, Calif., September 10, 2025--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-st...
3 Growth Companies To Consider With Insider Ownership Up To 39%
As the U.S. markets experience a pullback from record highs, with technology stocks leading the decline, investors are keenly observing how economic indicators and Federal Reserve policies might impac...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
